- Home
- FENC vs TVGN Comparison
FENC vs TVGN Comparison
Compare FENC & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- TVGN
- Stock Information
- Founded
- FENC 1996
- TVGN 2020
- Country
- FENC United States
- TVGN United States
- Employees
- FENC N/A
- TVGN N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- TVGN Blank Checks
- Sector
- FENC Health Care
- TVGN Finance
- Exchange
- FENC Nasdaq
- TVGN Nasdaq
- Market Cap
- FENC 156.9M
- TVGN 174.4M
- IPO Year
- FENC 2001
- TVGN N/A
- Fundamental
- Price
- FENC $6.65
- TVGN $1.42
- Analyst Decision
- FENC Strong Buy
- TVGN
- Analyst Count
- FENC 2
- TVGN 0
- Target Price
- FENC $14.00
- TVGN N/A
- AVG Volume (30 Days)
- FENC 53.9K
- TVGN 4.5M
- Earning Date
- FENC 03-20-2025
- TVGN 03-04-2025
- Dividend Yield
- FENC N/A
- TVGN N/A
- EPS Growth
- FENC N/A
- TVGN N/A
- EPS
- FENC N/A
- TVGN N/A
- Revenue
- FENC $49,348,000.00
- TVGN N/A
- Revenue This Year
- FENC $170.43
- TVGN N/A
- Revenue Next Year
- FENC $6.70
- TVGN N/A
- P/E Ratio
- FENC N/A
- TVGN N/A
- Revenue Growth
- FENC 278.09
- TVGN N/A
- 52 Week Low
- FENC $3.96
- TVGN $0.26
- 52 Week High
- FENC $11.49
- TVGN $8.49
- Technical
- Relative Strength Index (RSI)
- FENC 58.24
- TVGN 47.72
- Support Level
- FENC $6.57
- TVGN $1.48
- Resistance Level
- FENC $6.96
- TVGN $1.67
- Average True Range (ATR)
- FENC 0.26
- TVGN 0.12
- MACD
- FENC -0.02
- TVGN -0.01
- Stochastic Oscillator
- FENC 61.25
- TVGN 8.33
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.